Tautomycetin |
| Catalog No.GC11381 |
La tautomycétine est un inhibiteur puissant et spécifique de la PP1 avec une activité potentielle d'induction de l'apoptose.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 119757-73-2
Sample solution is provided at 25 µL, 10mM.
GlpBio Products Cited In Reputable Papers
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Product Documents
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Protocol
| Cell experiment [1]: | |
|
Cell lines |
Human primary T cells |
|
Preparation method |
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
1 μg/ml for 5 h |
|
Applications |
Tautomycetin possesses immunosuppressive activity to inhibit the proliferation of T cells by inhibition of IL-2 secretion. |
| Animal experiment [1]: | |
|
Animal models |
Rats after heterotopic cardiac transplantation |
|
Dosage form |
0.05 mg/kg. Tautomycetin solubilized in PBS or in microemulsion form for 30 days after heterocardiac transplantation. |
|
Application |
Immunosuppressive activity of tautomycetin is effective in an in vivo organ transplantation model (rats after heterotopic cardiac transplantation). |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Jae-Hyuck Shim, et al. Immunosuppressive effects of tautomycetin in vivo and in vitro via T cell-specific apoptosis induction. Proc Natl Acad Sci U S A. 2002 Aug 6; 99(16): 10617–10622. |
|
| Cas No. | 119757-73-2 | SDF | |
| Chemical Name | (S)-(2S,3S,4R,7S,8R,11R,13R,Z)-17-ethyl-4,8-dihydroxy-3,7,11,13-tetramethyl-6,15-dioxononadeca-16,18-dien-2-yl 3-hydroxy-3-(4-methyl-2,5-dioxo-2,5-dihydrofuran-3-yl)propanoate | ||
| Canonical SMILES | O[C@@H]([C@H](C)C(C[C@H]([C@H](C)[C@H](C)OC(C[C@@H](C1=C(C)C(OC1=O)=O)O)=O)O)=O)CC[C@@H](C)C[C@@H](C)CC(/C=C(C=C)/CC)=O | ||
| Formula | C33H50O10 | M.Wt | 606.75 |
| Solubility | Soluble in DMSO (supplied pre-dissolved in DMSO, 10mg/ml) | Storage | Desiccate at -20°C,protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
Complete Stock Solution Preparation Table
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6481 mL | 8.2406 mL | 16.4813 mL |
| 5 mM | 0.3296 mL | 1.6481 mL | 3.2963 mL |
| 10 mM | 0.1648 mL | 0.8241 mL | 1.6481 mL |
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Related Products
- GC32334 KB-5246
- GC32630 RP 54275 (2-Octadecyl-1H-indole-5-carboxylic acid)
- GC31739 Hispidol ((Z)-Hispidol)
- GC34404 GHRP-2 metabolite 1 ((D-Ala)-(D-beta-Nal)-Ala)
- GC15682 Chymostatin
- GC30028 Auxinole
- GC33881 Ro 31-9790 (GI4747)
- GC43382 DAz-2
- GC18902 Heronamide C
- GC18425 4-hydroxy Atorvastatin lactone
- GC37863 Urechistachykinin II
- GC32032 Hosenkoside K
- GC33512 Dihydrofluorescein diacetate
- GC18680 Lipoxin A4 methyl ester
- GC43080 C30 Ceramide (d18:1/30:0)
- GC30138 Meta-Topolin (m-Topolin)
- GC60269 NH-bis(PEG3-Boc)
Avis
Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *